Abstract
MDS-367 A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
